NRIX icon

Nurix Therapeutics

17.59 USD
+0.02
0.11%
At close Feb 14, 4:00 PM EST
After hours
17.59
+0.00
0.00%
1 day
0.11%
5 days
-9.10%
1 month
-5.43%
3 months
-34.51%
6 months
-19.75%
Year to date
-9.84%
1 year
90.99%
5 years
-7.47%
10 years
-7.47%
 

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Employees: 286

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

52% more call options, than puts

Call options by funds: $1.84M | Put options by funds: $1.21M

14% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 57

9% more capital invested

Capital invested by funds: $1.4B [Q2] → $1.52B (+$121M) [Q3]

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

1% less funds holding

Funds holding: 173 [Q2] → 171 (-2) [Q3]

7.98% less ownership

Funds ownership: 112.99% [Q2] → 105.01% (-7.98%) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$17
3%
downside
Avg. target
$31
74%
upside
High target
$36
105%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Morgan Stanley
Terence Flynn
53% 1-year accuracy
9 / 17 met price target
3%downside
$17
Equal-Weight
Maintained
3 Feb 2025
RBC Capital
Gregory Renza
29% 1-year accuracy
24 / 84 met price target
54%upside
$27
Outperform
Maintained
29 Jan 2025
JP Morgan
Eric Joseph
43% 1-year accuracy
12 / 28 met price target
71%upside
$30
Overweight
Maintained
29 Jan 2025
Stifel
Stephen Willey
50% 1-year accuracy
9 / 18 met price target
105%upside
$36
Buy
Maintained
29 Jan 2025
Needham
Gil Blum
17% 1-year accuracy
28 / 168 met price target
59%upside
$28
Buy
Maintained
29 Jan 2025

Financial journalist opinion

Based on 5 articles about NRIX published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 week ago
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 12:40 p.m. ET.
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Negative
Zacks Investment Research
2 weeks ago
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.77 per share a year ago.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 weeks ago
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
R eported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66 th American Society of Hematology Annual Meeting
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Neutral
GlobeNewsWire
3 weeks ago
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Neutral
Seeking Alpha
1 month ago
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Neutral
GlobeNewsWire
1 month ago
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco.
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Neutral
GlobeNewsWire
2 months ago
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Neutral
GlobeNewsWire
2 months ago
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, December 9, 2024.
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Charts implemented using Lightweight Charts™